Meeting
2020 ASCO Virtual Scientific Program
Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: Phase I and expansion cohort results.
Authors
Gerald Steven Falchook
Sarah Cannon Research Institute at HealthONE, Denver, CO
Gerald Steven Falchook , Johanna C. Bendell , Susanna Varkey Ulahannan , Shiraj Sen , Rasa Vilimas , Kristina Kriksciukaite , Laura Mei , Goran Jerkovic , Nenad Sarapa , Mark Bilodeau , Jeffrey Bloss , Anish Thomas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT03221400
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3515)
DOI
10.1200/JCO.2020.38.15_suppl.3515
Abstract #
3515
Poster Bd #
245
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2012 ASCO Annual Meeting
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.
First Author: Herlinde Dumez
Poster
2012 ASCO Annual Meeting
First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors.
First Author: Michael Anthony Carducci